Cyanidin-3-O-Glucoside improves the viability of human islet cells treated with amylin or Aβ1-42 in vitro.
Adult
Aged
Amyloid beta-Peptides
/ toxicity
Anthocyanins
/ pharmacology
Autophagy
/ drug effects
Biomarkers
/ metabolism
Cell Survival
/ drug effects
Cells, Cultured
Female
Gene Expression Regulation
/ drug effects
Glucosides
/ pharmacology
Heme Oxygenase-1
/ genetics
Humans
Inflammation
/ pathology
Insulin Secretion
/ drug effects
Islet Amyloid Polypeptide
/ toxicity
Islets of Langerhans
/ cytology
Middle Aged
Peptide Fragments
/ toxicity
Reactive Oxygen Species
/ metabolism
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
05
2021
accepted:
22
09
2021
entrez:
6
10
2021
pubmed:
7
10
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Islet transplantation is being considered as an alternative treatment for type 1 diabetes. Despite recent progress, transplant recipients continue to experience progressive loss of insulin independence. Cyanidin-3-O-Glucoside (C3G) has shown to be protective against damage that may lead to post-transplant islet loss. In this study, human islets cultured with or without C3G were treated with human amylin, Aβ1-42, H2O2, or rapamycin to mimic stresses encountered in the post-transplant environment. Samples of these islets were collected and assayed to determine C3G's effect on cell viability and function, reactive oxygen species (ROS), oxidative stress, amyloid formation, and the presence of inflammatory as well as autophagic markers. C3G treatment of human islets exposed to either amylin or Aβ1-42 increased cell viability (p<0.01) and inhibited amyloid formation (p<0.01). A reduction in ROS and an increase in HO-1 gene expression as well as in vitro islet function were also observed in C3G-treated islets exposed to amylin or Aβ1-42, although not significantly. Additionally, treatment with C3G resulted in a significant reduction in the protein expression of inflammatory markers IL-1β and NLRP3 (p<0.01) as well as an increase in LC3 autophagic marker (p<0.05) in human islets treated with amylin, Aβ1-42, rapamycin, or H2O2. Thus, C3G appears to have a multi-faceted protective effect on human islets in vitro, possibly through its anti-oxidant property and alteration of inflammatory as well as autophagic pathways.
Identifiants
pubmed: 34614009
doi: 10.1371/journal.pone.0258208
pii: PONE-D-21-17270
pmc: PMC8494376
doi:
Substances chimiques
Amyloid beta-Peptides
0
Anthocyanins
0
Biomarkers
0
Glucosides
0
Islet Amyloid Polypeptide
0
Peptide Fragments
0
Reactive Oxygen Species
0
amyloid beta-protein (1-42)
0
cyaniding 3-glucoside
0
Heme Oxygenase-1
EC 1.14.14.18
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0258208Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Cell Transplant. 2008;17(12):1323-36
pubmed: 19364070
Ther Drug Monit. 2005 Feb;27(1):35-7
pubmed: 15665744
Methods Mol Biol. 2008;445:77-88
pubmed: 18425443
Autophagy. 2011 Jan;7(1):12-6
pubmed: 20935505
Regul Pept. 1993 Jun 11;45(3):363-70
pubmed: 8351401
J Endocrinol. 2017 Dec;235(3):237-249
pubmed: 28931557
Am J Transplant. 2015 Jun;15(6):1519-30
pubmed: 25833002
Am J Pathol. 2011 Jan;178(1):140-9
pubmed: 21224052
Free Radic Res. 2002 Nov;36(11):1229-41
pubmed: 12592675
J Agric Food Chem. 2013 Sep 18;61(37):8765-72
pubmed: 23930663
Metabolism. 1999 Apr;48(4):448-54
pubmed: 10206436
Transplantation. 2012 Jan 27;93(2):219-23
pubmed: 22193043
Diabetes. 1990 May;39(5):634-8
pubmed: 2185112
Ultrastruct Pathol. 2005 Nov-Dec;29(6):525-33
pubmed: 16316953
Diabetes. 2007 Jan;56(1):65-71
pubmed: 17192466
Ups J Med Sci. 2003;108(3):193-203
pubmed: 15000457
J Neurochem. 2001 Feb;76(4):1050-6
pubmed: 11181824
Acta Diabetol. 2015 Oct;52(5):917-27
pubmed: 25808641
Diabetes. 2004 Dec;53 Suppl 3:S233-8
pubmed: 15561917
Proc Natl Acad Sci U S A. 1990 Jul;87(13):5036-40
pubmed: 2195544
N Engl J Med. 2008 Aug 28;359(9):977-9
pubmed: 18753660
Cell Calcium. 2014 Nov;56(5):416-27
pubmed: 25224501
Transplantation. 2015 Mar;99(3):508-14
pubmed: 25680088
Endocrinology. 2016 Feb;157(2):560-9
pubmed: 26653569
Diabetologia. 1989 Apr;32(4):240-4
pubmed: 2668077
Annu Rev Pharmacol Toxicol. 1997;37:517-54
pubmed: 9131263
J Med Food. 2012 Mar;15(3):288-98
pubmed: 22181073
Am J Pathol. 2010 Feb;176(2):861-9
pubmed: 20042670
FEBS J. 2006 Aug;273(15):3614-24
pubmed: 16884500
Nature. 1994 Apr 21;368(6473):756-60
pubmed: 8152488
PLoS One. 2012;7(10):e46646
pubmed: 23071605
Autophagy. 2016;12(1):1-222
pubmed: 26799652
Ann N Y Acad Sci. 2000;926:1-12
pubmed: 11193023
Pancreas. 2007 Nov;35(4):e1-9
pubmed: 18090225
Diabetes. 2004 Oct;53(10):2559-68
pubmed: 15448084
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4305-10
pubmed: 20160085
J Agric Food Chem. 2005 Mar 23;53(6):2327-32
pubmed: 15769176
Molecules. 2016 Aug 31;21(9):
pubmed: 27589714
J Chromatogr A. 2001 Mar 2;910(2):265-73
pubmed: 11261721
FEBS Lett. 2013 Apr 17;587(8):1106-18
pubmed: 23380070
Cell Transplant. 2017 Feb 16;26(2):319-326
pubmed: 27743446
J Agric Food Chem. 2011 Jan 26;59(2):537-45
pubmed: 21166417
J Neurosci. 2004 Jun 16;24(24):5579-84
pubmed: 15201330
Trends Cell Biol. 2007 Sep;17(9):422-7
pubmed: 17804237
Diabetes Res. 1988 Dec;9(4):151-9
pubmed: 3073901
Diabetologia. 1995 May;38(5):543-9
pubmed: 7489836
Curr Med Chem. 2013;20(9):1127-46
pubmed: 23317098
J Mol Biol. 2016 May 8;428(9 Pt A):1714-24
pubmed: 26876603
Pharmacol Res. 2015 Aug;98:31-8
pubmed: 25107501
Amyloid. 2012 Jun;19(2):87-93
pubmed: 22587435